LYSOGENE
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.
LYSOGENE
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2009-01-01
Address:
Neuilly-sur-seine, Ile-de-France, France
Country:
France
Website Url:
http://www.lysogene.com
Total Employee:
11+
Status:
Active
Contact:
+33 1 56 88 52 86
Total Funding:
30.26 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Similar Organizations
AMR Centre
AMR Centre is a joint private-public initiative to support/accelerate the development of new antibiotics and diagnostics.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Aristea Therapeutics
Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.
Calypso Biotech
Calypso Biotech's vision is to give new hope to patients suffering from severe gastro-intestinal diseases.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
ETHRIS
ETHRIS is a technical innovator in the emerging field of mRNA therapeutics and LNP delivery.
FinVector
FinVector is a world leader in the research and development of Viral-Based Gene Therapy products.
IAG, Image Analysis Group
IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Pharnext
Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
POLYNEURON
Polyneuron is a pharmaceutical company, committed to the development of a new drug class for the treatment of autoimmune disorders.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Stock Details
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - LYSOGENE
Bpifrance
Bpifrance investment in Post-IPO Debt - LYSOGENE
Novo Holdings
Novo Holdings investment in Series A - LYSOGENE
Sofinnova Investments
Sofinnova Investments investment in Series A - LYSOGENE
Official Site Inspections
http://www.lysogene.com Semrush global rank: 3.78 M Semrush visits lastest month: 3.56 K
- Host name: cluster013.ovh.net
- IP address: 213.186.33.24
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "LYSOGENE"
LYSOGENE - Crunchbase Company Profile & Funding
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients …See details»
Lysogene Company Profile 2024: Valuation, …
Lysogene SA is a biotechnology company. It is engaged in research and clinical development of gene therapy for neurodegenerative disorders. The group is …See details»
Lysogene - Devex
Learn more about Lysogene's jobs, projects, latest news, contact information and geographical presence. Their mission is to discover and develop innovative therapies to transform the lives of...See details»
Lysogene Company Profile - Office Locations, Competitors …
May 26, 2020 · Lysogene is a company that provides research and clinical development of gene therapy for neurodegenerative disorders. It offers AAV vectors for safely delivering genetic …See details»
LYSOGENE - Funding, Financials, Valuation & Investors
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.See details»
Lysogene - RooneyPartners
Lysogene (Paris: LYS) is a clinical-stage biopharmaceutical company based in France that seeks to develop cutting-edge gene therapy treatments to battle neurodegenerative disorders with high unmet medical needs such as …See details»
Lysogene Reports Full Year 2020 Financial Results and …
Mar 31, 2021 · Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced its 2020 full-year results, …See details»
How a Former Financial Consultant Built a …
Dec 14, 2016 · Lysogene, which received an orphan drug designation and rare pediatric disease designation from the Food and Drug Administration, is one of the companies leading the way. The company is based in France, but recently …See details»
Lysogene and Yeda enter gene therapy licencing …
Apr 14, 2022 · Lysogene has been partnering with the Weizmann Institute of Science since 2020 to develop a new adeno-associated virus (AAV) gene therapy approach to treat neuronopathic Gaucher disease and PD, as well as various …See details»
Lysogene Announces the Conversion of the …
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided to convert the...See details»
Lysogene Provides Updates and Topline Results …
Nov 18, 2022 · Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance...See details»
France: Lysogene enters into a loan agreement of €15 …
Dec 24, 2021 · Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a …See details»
Lysogene Reports Full Year 2020 Financial Results and
Mar 31, 2021 · Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announced its 2020 full-year results, approved by the Board of Directors on …See details»
Lysogene : Announces Favorable DSMB Review …
Nov 30, 2022 · Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to …See details»
Lysogene Reports Full Year 2021 Financial Results
Mar 31, 2022 · Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its 2021 full-year financial …See details»
Lysogene looks for saving grace after trial flop - Fierce Biotech
Dec 7, 2022 · On the heels of Lysogene’s lead gene therapy candidate flunking a phase 2/3 study, the French biotech has suspended trading of its shares and is seeking potential …See details»
LYSOGENE Reports First Half 2021 Financial Results and …
Sep 24, 2021 · Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced its financial results for the …See details»
Lysogen - Wikipedia
A lysogen or lysogenic bacteria is a bacterial cell which can produce and transfer the ability to produce a phage. [1] . A prophage is either integrated into the host bacteria 's chromosome or …See details»
Lysogene: Conversion of the Safeguard Proceedings Into …
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard …See details»
Lysogene Provides Medical Update - Business Wire
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides a medical update.See details»